Bo Björkstrand

TL;DR: New criteria for response and progression have been developed as a result of discussions between representatives of the Myeloma Subcommittee of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) and representatives ofThe Myelomas Working Committee of the Autologousblood and marrow transplant Registry (ABMTR) and the International Bone Marrowtransplant Registry (IBMTR).

TL;DR: Reasons for the reduced transplant‐related mortality appeared to be fewer deaths owing to bacterial and fungal infections and interstitial pneumonitis, in turn a result of earlier transplantation and less prior chemotherapy, which may also play a role.

TL;DR: While RIC is feasible, heavily pretreated patients and patients with progressive disease do not benefit, suggesting that a graft-versus-myeloma effect is important.

TL;DR: MPT had a significant antimyeloma effect, but this did not translate into improved survival, and most quality of life outcomes improved equally in both arms, apart from constipation, which was markedly increased in the MPT arm.

TL;DR: It is proposed that autologous NK cells expanded ex vivo deserve further attention as a possible new treatment modality for MM.